{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:41:43Z","timestamp":1792244503451,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006775","name":"GE HealthCare Technologies Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clbc.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:59:38Z","timestamp":1789721978000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Utility of [18F]Fluoroestradiol PET\/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5048-2819","authenticated-orcid":false,"given":"Hannah M.","family":"Linden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-101X","authenticated-orcid":false,"given":"Sophia R.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-0471","authenticated-orcid":false,"given":"Stephanie M.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"La Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8898-8468","authenticated-orcid":false,"given":"Peter S.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin F.","family":"Peddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-1934","authenticated-orcid":false,"given":"Joanne E.","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Brenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-3384","authenticated-orcid":false,"given":"Amol M.","family":"Takalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-1440","authenticated-orcid":false,"given":"Julia E.","family":"McGuinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5466-156X","authenticated-orcid":false,"given":"Edgar","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1613-5909","authenticated-orcid":false,"given":"Lanell M.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence Z.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-7960","authenticated-orcid":false,"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Ulaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clbc.2026.09.008_bib0001","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2026.09.008_bib0002","article-title":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in oncology","volume":"2","year":"2026","journal-title":"Breast Cancer Version"},{"issue":"1","key":"10.1016\/j.clbc.2026.09.008_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41523-023-00578-3","article-title":"Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer","volume":"9","author":"Ma","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"28","key":"10.1016\/j.clbc.2026.09.008_bib0004","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, Human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2026.09.008_bib0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clbc.2026.09.008_bib0006","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, Human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.09.008_bib0007","unstructured":"GE HealthCare. CERIANNA (fluoroestradiol F18) injection prescribing information 2025. Available from: https:\/\/www.gehealthcare.com\/-\/jssmedia\/gehc\/us\/files\/products\/nuclear-imaging-agents\/cerianna\/cerianna-pi.pdf?rev=-1. Accessed: May 22, 2026."},{"key":"10.1016\/j.clbc.2026.09.008_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2019.10.024","article-title":"Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition","volume":"126","author":"Boers","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2026.09.008_bib0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nucmedbio.2020.02.007","article-title":"The quest for improving the management of breast cancer by functional imaging: the discovery and development of 16alpha-[(18)F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review","volume":"92","author":"Katzenellenbogen","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.clbc.2026.09.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0967","article-title":"Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16alpha-18F-fluoro-17beta-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications","author":"Kurland","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clbc.2026.09.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/tbj\/4333748","article-title":"Real-world practice patterns in diagnosis and first-line treatment in metastatic breast cancer","volume":"2026","author":"Manohar","year":"2026","journal-title":"Breast J"},{"issue":"12","key":"10.1016\/j.clbc.2026.09.008_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122644","article-title":"Hormone receptor loss in breast cancer: molecular mechanisms, clinical settings, and therapeutic implications","volume":"9","author":"Zattarin","year":"2020","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.clbc.2026.09.008_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2967\/jnumed.123.265420","article-title":"Summary: appropriate use criteria for estrogen receptor\u2013targeted PET imaging with 16\u03b1-18F-fluoro-17\u03b2-fluoroestradiol","volume":"64","author":"Ulaner","year":"2023","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.clbc.2026.09.008_bib0014","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.semnuclmed.2022.03.002","article-title":"16alpha-18F-fluoro-17beta-fluoroestradiol (FES): clinical applications for patients with breast cancer","volume":"52","author":"Ulaner","year":"2022","journal-title":"Semin Nucl Med"},{"issue":"18","key":"10.1016\/j.clbc.2026.09.008_bib0015","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1200\/JCO.2005.04.3810","article-title":"Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer","volume":"24","author":"Linden","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2026.09.008_bib0016","article-title":"The role of estrogen receptor-targeted PET with 16alpha-(18)F-fluoro-17beta-estradiol in predicting response to endocrine therapies in metastatic breast cancer: a metaanalysis","author":"Specht","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clbc.2026.09.008_bib0017","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.267913","article-title":"Impact of (18)F-FES PET\/CT on clinical decisions in the management of recurrent or metastatic breast cancer","author":"Ryu","year":"2024","journal-title":"J Nucl Med."},{"issue":"12_Supplement","key":"10.1016\/j.clbc.2026.09.008_bib0018","volume":"31","author":"Bidard","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clbc.2026.09.008_bib0019","first-page":"933","article-title":"Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy","volume":"2","author":"Mortimer","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clbc.2026.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2967\/jnumed.117.198846","article-title":"(18)F-fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients","volume":"59","author":"Nienhuis","year":"2018","journal-title":"J Nucl Med"},{"issue":"17","key":"10.1016\/j.clbc.2026.09.008_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173025","article-title":"Estrogen-receptor loss and ESR1 mutation in Estrogen-receptor-positive metastatic breast cancer and the effect on overall survival","volume":"16","author":"Westenend","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clbc.2026.09.008_bib0022","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s43018-021-00229-1","article-title":"Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment","volume":"2","author":"Pasha","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clbc.2026.09.008_bib0023","article-title":"Summary: SNMMI procedure Standard\/EANM practice guideline for estrogen receptor imaging of patients with breast cancer using 16alpha-[(18)F]fluoro-17beta-estradiol PET","author":"Mankoff","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clbc.2026.09.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-024-07058-1","article-title":"Predictive and prognostic value of (18)F-FES PET\/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4\/6 inhibitors","author":"Jeong","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clbc.2026.09.008_bib0025","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.268984","article-title":"Intrapatient 16alpha-[(18)F]fluoro-17beta-estradiol PET heterogeneity as a prognostic factor for endocrine therapy response and survival in patients with estrogen receptor-positive metastatic breast cancer","author":"van Geel","year":"2025","journal-title":"J Nucl Med"},{"issue":"12_Supplement","key":"10.1016\/j.clbc.2026.09.008_bib0026","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-PS11-01","article-title":"Abstract PS11-01: [18F]fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: results from EAI142","volume":"31","author":"Linden","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clbc.2026.09.008_bib0027","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.240253","article-title":"Evaluating automated tools for lesion detection on (18)F fluoroestradiol PET\/CT images and assessment of concordance with standard-of-care imaging in metastatic breast cancer","volume":"7","author":"Miller","year":"2025","journal-title":"Radiol Imaging Cancer"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:54:36Z","timestamp":1792241676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1526820926001710"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.09.008","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Utility of [18F]Fluoroestradiol PET\/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}